AtriCure to Present at the Morgan Stanley Global Healthcare Conference

Aug. 18, 2016 4:01 pm


AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 14, 2016. Management is scheduled to present at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 75,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer
awade@atricure.com
or
Investor Relations Contact
Gilmartin Group
Lynn Pieper Lewis, 415-937-5402
lynn@gilmartinir.com

Business Wire
August 18, 2016 - 4:01 PM EDT


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market